Daxor (DXR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 6.24K
• Price to Earnings (P/E): 36.0
• Beta (1Y): 0.46
• Revenue Growth: -97.00%
• EPS Growth: 3.43%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 4,962,245
• 10 Day Avg. Volume: 6,607
• 30 Day Avg. Volume: 6,240
• PEG Ratio: 0.85
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 17.48
• P/FCF Ratio: 1.45K
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 68.40
• Enterprise Value/Gross Profit: 76.40
• Enterprise Value/Ebitda: 14.61
• 1Y Price Target: $22.00
• Price Target Upside: 65.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.8
• Revenue Forecast (FY): $50.27M

• Rating: 55 Neutral
• Price Target: ―

Daxor's stock score reflects a mixed performance. The strongest factor is the positive earnings call, showcasing significant revenue growth and strategic initiatives. However, financial performance is hindered by operational challenges and cash flow volatility. Technical analysis indicates a lack of strong momentum, and high valuation metrics suggest potential overvaluation.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion and financial health.

Strong Balance Sheet

A strong balance sheet with no debt enhances financial stability and reduces risk, allowing for potential future investments and growth opportunities.

Expansion of Clinical Partnerships

Expanding clinical partnerships increases market penetration and technology adoption, driving sustained revenue growth and competitive advantage.

Negative Factors

Volatile Cash Flows

Volatile cash flows can hinder operational flexibility and investment capacity, posing a risk to financial stability and growth initiatives.

Operational Challenges

Operational challenges can lead to inefficiencies and increased costs, potentially impacting profitability and long-term business sustainability.

Delay in FDA Approval

Delays in FDA approval can postpone product launches and revenue realization, affecting growth prospects and competitive positioning.

Daxor Business Overview & Revenue Model

Company Description

Daxor Corporation (DXR) is a medical instrumentation and biotechnology company that specializes in blood volume analysis technology. The company focuses on advancing healthcare by providing innovative diagnostic tools and services that enhance the understanding and treatment of various medical conditions. Daxor's flagship product, the BVA-100, is an FDA-cleared diagnostic device that measures human blood volume, aiding in the precise assessment of fluid management in patients.

How the Company Makes Money

Daxor Corporation generates revenue primarily through the sale and leasing of its proprietary blood volume analysis systems, such as the BVA-100. Additionally, the company earns income by providing related services, including testing and analysis of blood samples. This includes contracts with hospitals, clinics, and medical research institutions that utilize their technology for improved clinical decision-making. Daxor may also benefit from partnerships or collaborations with healthcare providers and research organizations that contribute to its growth and market reach. Factors such as regulatory approvals, technological advancements, and the increasing demand for precision in medical diagnostics play a significant role in its revenue generation.

Daxor Financial Statement Overview

Summary

Daxor demonstrates a mixed financial performance. The income statement highlights operational challenges despite recent profitability, with a notable improvement in net profit margin. The balance sheet is strong with no debt and a high equity ratio, suggesting financial stability. Cash flows are volatile but show signs of improvement, though converting income into cash remains a challenge.

Income Statement

Daxor's income statement shows a volatile revenue trajectory, with significant swings in total revenue from negative to positive figures over the years. The gross profit margin is strong at 100% for 2024, indicating that all revenue is gross profit, but a negative EBIT margin suggests high operational costs. The net profit margin improved from previous losses, highlighting recent profitability. However, the revenue growth rate is unstable, with a recent recovery in 2024.

Balance Sheet

The balance sheet reflects a robust equity position with a high equity ratio and no debt reported for 2024, indicating financial stability. Return on Equity (ROE) is positive, reinforcing profitability. The absence of debt lowers financial risk, but the company's ability to leverage for growth is limited. Asset growth is consistent, supporting long-term stability.

Cash Flow

Daxor's cash flow statement shows fluctuating free cash flow, with a positive shift in 2024. The operating cash flow to net income ratio is low, indicating potential challenges in converting income into cash. The free cash flow to net income ratio is also low, suggesting limited cash generation relative to reported profits. The overall cash flow trajectory is improving but remains volatile.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	713.65K	2.13M	34.59M	-353.36K	-2.62M	-2.81M
Gross Profit	639.01K	2.13M	34.41M	-1.44M	-3.62M	-3.49M
EBITDA	3.34M	2.06M	329.74K	6.11M	4.75M	-1.72M
Net Income	1.80M	536.33K	280.64K	5.18M	4.75M	-1.71M
Balance Sheet
Total Assets	35.90M	36.63M	34.87M	30.26M	24.98M	16.55M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	0.00	710.70K	617.80K
Total Debt	262.93K	729.97K	755.66K	1.23M	3.02M	170.69K
Total Liabilities	272.43K	840.30K	858.76K	1.29M	3.83M	877.69K
Stockholders Equity	35.63M	35.79M	34.01M	28.97M	21.15M	15.68M
Cash Flow
Free Cash Flow	-35.01K	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Operating Cash Flow	-35.01K	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Investing Cash Flow	2.20M	1.94M	2.75M	2.69M	74.76K	367.93K
Financing Cash Flow	-1.39M	-25.69K	3.66M	58.60K	2.85M	3.07M

Daxor Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Neutral. The current price of 13.28 is above the 20-day moving average (MA) of 13.11, above the 50-day MA of 12.50, and above the 200-day MA of 9.55, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 50.11 is Neutral, neither overbought nor oversold. The STOCH value of 65.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DXR.

Daxor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$5.13B	44.81	8.30%	―	11.49%	-2.89%
PDEX	72 Outperform	$105.53M	9.72	30.92%	―	23.65%	120.84%
MHUA	64 Neutral	$7.24M	0.73	5.90%	―	-4.99%	-19.11%
DXR	55 Neutral	―	36.00	5.26%	―	-97.00%	3.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	45 Neutral	$35.91M	―	-329.45%	―	98.61%	-1.98%
MLSS	38 Underperform	$29.73M	-4.35	-123.50%	―	7.84%	-43.00%